



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>5</sup> :</b>  <b>G01N 33/53, 33/546, 33/569</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/15766</b>  <b>(43) International Publication Date:</b> 17 October 1991 (17.10.91)
<b>(21) International Application Number:</b> PCT/EP91/00671 <b>(22) International Filing Date:</b> 9 April 1991 (09.04.91) <b>(30) Priority data:</b> 9007966.6                      9 April 1990 (09.04.90)                      GB <b>(71) Applicant (for GB only):</b> HOLMES, Michael, John [GB/GB]; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB). <b>(71) Applicant (for all designated States except US):</b> DYNAL A.S [NO/NO]; Harbitzalleen 3 Skoyen, N-0275 Oslo 2 (NO). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> AFSETH, John [NO/NO]; Frognersterveien 7D, N-0387 Oslo 3 (NO). CAIGNAULT, Laurent [FR/FR]; 7, rue Binder-Mestro, F-60750 Choisy-au-Bac (FR). FUNDERUD, Steinar [NO/NO]; Gravdalsveien 15, N-0756 Oslo 7 (NO). MORTADA, Mohamad [LB/FR]; 5, rue Pierre et Marie-Curie, Apt. 64 - 7ème étage, F-60200 Compiègne (FR).		<b>(74) Common Representatives:</b> HOLMES, Michael, John et al.; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> ANTIGEN/ANTI-ANTIGEN CLEAVAGE  <b>(57) Abstract</b>  <p>The present invention provides a method of cleaving an antigen/anti-antigen or hapten/anti-hapten linkage joining two particles comprising reacting said linkage with a secondary antibody, or fragment thereof, binding to said anti-antigen or anti-hapten, and a kit for performing such a method. The method of the invention has particular utility in the separation of cells.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

Antigen/Anti-Antigen Cleavage

5

The invention relates to a method of cleaving antigen/anti-antigen and hapten/anti-hapten linkages.

10 In biochemistry and related fields it is frequently desirable to link two chemical or biochemical entities, for example in isolation or purification or in the immobilisation of substances on solid supports. In particular it is often required to isolate cells by attaching them to substances assisting in their  
15 isolation and to isolate the cells subsequently in viable form.

Such linkage is often accomplished using affinity binding, that is by means of a pair of binding partners  
20 which are, for example, separately attached to the substances to be linked and which bind when brought into contact. Alternatively one of the binding partners may form a part of the entity requiring linkage, for example a molecule on a cell surface. A number of binding  
25 partner systems are known, for example antigen-antibody, enzyme-substrate, ligand-receptor interactions on cells and biotin-avidin binding. Antigen-antibody binding partners are however most frequently used in this regard, although the use of a hapten/anti-hapten binding  
30 pair has also recently been proposed.

Affinity binding systems are generally reversible, but it has been found, however, that particularly with antigen-antibody binding partners such linkages are  
35 difficult to reverse without destructive effects. Thus, whilst a linkage having a weak interaction strength (eg  $K_a = 10^{-4}$ - $10^{-6}$  M<sup>-1</sup>) can be broken under mild conditions for

example by competition with an analogue of the "ligand" binding partner, where the linkage is stronger (eg  $K_a > 10^{-8} M^{-1}$ ), competitions kinetics do not suffice and more drastic conditions are necessary eg pH modification, salting out, in order to modify the conformation of the binding partner(s) and thereby reduce the interaction strength. For the cleavage method to be of use, the conformational changes induced during such a cleavage step must be reversible, and the binding partners should recover their functions upon return to the original conditions. Unfortunately, in the case of antigen/antibody binding, which must be of the order of at least  $10^{-8} M^{-1}$  to be effective in allowing specific and rapid separation, whilst the antibody molecule can usually recover its native activity following such a cleavage treatment the antigen frequently is irreversibly altered and its native properties are lost. This is particularly a problem in the separation of cells or bacteria where it is important to maintain viability. Moreover, it is often desirable to be able to liberate the entities being linked in an unmodified native form, i.e. without any foreign substances remaining attached. This is particularly true in the case of cell isolation, where any foreign substances remaining attached to the surface of the liberated cells tend to interfere in cell reproduction and viability.

Cells are commonly linked, or bound, by employing antibodies which bind to antigens or haptens on the cell surface. As mentioned above antigen/antibody linkages are particularly difficult to reverse, and methods which cleave the antigen/antibody in such a manner that a part of the antibody remains attached are not particularly suited for use in cell isolation and separation procedures. Thus there exists a need for an improved method of cleaving antigen/anti-antigen or hapten/anti-hapten linkages with minimal destructive effect and in a

manner which leaves the antigen or hapten and anti-antigen or anti-hapten binding partners intact.

We have now found that the linkages in antigen/anti-antigen or hapten/anti-hapten linkage systems may readily be broken by reacting the linkage system with an antibody directed against the anti-antigen or anti-hapten binding partner, or with a fragment thereof which retains binding activity. This has the advantage that the linkage is broken under mild conditions avoiding destruction of protein or other sensitive species present, and since the bonding between the antigen or hapten and its anti-antigen or anti-hapten binding partner is simply reversed, there is no problem with unwanted parts of the anti-antigen or anti-hapten remaining attached to the antigen or hapten binding partner or vice versa. This improvement in cleavage of the antigen/hapten linkage systems enables advantage to be taken of anti-antigen or anti-hapten specificity in isolating the desired entity in unmodified form from a complex mixture.

In particular, where one of the binding partners is a molecule on a cell surface, the cell can be bound, for example to a reporter substance or a solid support, and subsequently liberated with its reproductive potential undiminished.

According to the present invention, therefore, there is provided a method of cleaving an antigen/anti-antigen or hapten/anti-hapten linkage joining two particles comprising reacting said linkage with an secondary antibody, or fragment thereof, binding to said anti-antigen or anti-hapten.

35

The term "particles" as used herein means particulate bodies such as cells, sub-cellular components, polymer

particles or other solid supports e.g. magnetic particles. While not wishing to be bound by theoretical explanations, it is possible that the action of the secondary antibody is assisted by strain on the affinity binding caused by relative movement of the two masses joined by the linkage to be broken. The linkage is thus destabilised, thereby facilitating detachment and preventing re-association. The secondary antibody may also act by binding to free antigenic sites unbound by the anti-antigen/anti-hapten thereby contributing to the destabilisation of the linkage.

In this specification, the terms anti-antigen and anti-hapten are intended to include complete anti-antigen or anti-hapten antibodies or any antigen or hapten binding fragments thereof, e.g. F(ab)<sub>2</sub>, Fab or Fv fragments (the Fv fragment is defined as the "variable" region of the antibody which comprises the antigen or hapten binding site.). The term "hapten" as used herein encompasses any small molecule which cannot by itself stimulate antibody synthesis but which will combine with an antibody formed by immunising an animal with an antigenic conjugate of the hapten and some antigenic substance, e.g. a protein such as keyhole limpet haemocyanin.

The secondary, linkage-cleaving, antibody directed against the anti-antigen or anti-hapten, (hereinafter referred to as the "secondary antibody") may be employed as the complete antibody, IgG and IgM antibodies being particularly preferred. Alternatively any fragments of the secondary antibody which retain binding activity may be used, for example F(ab)<sub>2</sub>, Fab or Fv fragments.

The secondary antibody is preferably directed against the Fab region of the anti-antigen or anti-hapten, but antibodies binding to any part of the anti-antigen or

anti-hapten may be used. The secondary antibody may moreover be specifically directed against a particular part of the anti-antigen or anti-hapten molecule such as for example the kappa or lambda ( $\kappa$  or  $\lambda$ ) light chains or even against a specific variable constant region within a given light chain.

Where the anti-hapten or anti-antigen has been used to attach a reporter substance or other species to the target hapten or antigen and the products cleaved from the target substance are water-soluble it may be advantageous for the secondary antibody (or fragment thereof) to be attached to particles, especially magnetic particles, to assist removal of the cleavage products from solution. Dynabeads (Dynal AS, Oslo) are particularly suitable for such use.

The secondary antibody may be mono- or polyclonal. The use of polyclonal sera has the advantage that since there are a number of different antibodies directed against different epitopes on the anti-antigen or anti-hapten, the binding of the secondary antibody or fragment, and thereby the efficacy of the method, is improved.

The new method of the invention may be used in the fields of analysis, diagnosis and cell isolation. For example, the method may be used in the isolation of infectious agents such as bacteria or viruses in order to quantitate them or characterise their infectivity, toxicity or susceptibility to drug treatment. The method can also be used for isolation of malignant cells or cell populations specific for different diseases and to characterise these cells further without interference from other contaminating cells. Also, the method may be used to isolate protective cell populations from an individual or from a group of individuals; the isolated

population can then be expanded and/or potentiated before being returned to the patient under treatment. Such protective cell populations can for example be monocytes/macrophages, lymphocytes or bone marrow stem  
5 cells. As regards analytical applications, the method of the invention may be used in quantification and morphological analyses or in immunochemical staining studies employing both immunological and non-immunological markers.

10

As previously mentioned, the method of the invention is particularly suited to cell isolation, particularly in the possible selection of desirable cells using antibodies directed against the cells to be isolated (as  
15 opposed to negative selection procedures where unwanted cells are removed from a cell preparation using antibodies specific for the unwanted cells).

20

It has been proposed to positively isolate desired cells using magnetic beads coated with an antibody directed against a cell surface antigen, thus binding the desired cells, the magnetic particles and attached cells being separated from other cells by magnetic aggregation and the cells being liberated from the magnetic particles to  
25 leave a positively selected population of cells. In particular in PCT/EP90/02327 there is described such a method for the selection of haemopoietic stem cells from bone marrow and other mixed cell populations. In such methods, the magnetic particles are advantageously the  
30 superparamagnetic, monodisperse particles sold as Dynabeads (Dynal AS, Oslo).

35

Up to now, to liberate cells from the particles, the cell/particle "rosettes" have usually been incubated overnight at 37°C to effect separation of the cells from the particles. In some cases the cells detach from the particles but in many cases they do not and such poor

recovery makes difficult the isolation of poorly represented cell sub-populations. We have now found that the new method of the invention is particularly suited for detaching the bound cells from the magnetic particles.

According to a second aspect of the invention there is therefore provided a method of positively isolating a target cell type from a mixed population of cells wherein an anti-antigen is bound to an antigen on said target cell, said anti-antigen being attached to magnetic particles, before or after binding to said target cells, whereby to link said particles to said cells, the magnetic particles and attached cells are isolated from the mixed population of cells by magnetic aggregation and the target cell is released from said magnetic particle by the addition of an antibody, or fragment thereof, binding to said anti-antigen.

Although particularly suited to the isolation of haemopoietic stem cells, the method of the invention may be applied to the isolation of any prokaryotic or eukaryotic cells or viruses from biological or artificial media, including whole blood, buffy coat and cell suspensions obtained by density gradient centrifugation. Moreover it should be noted that the method according to the invention may be applied to the isolation and subsequent liberation of sub-cellular components such as mitochondria and nuclei, and macromolecules such as proteins and nucleic acids. The entity to be isolated may be naturally antigenic or may be made so artificially.

The amount of secondary antibody required for optimal cleavage will of course vary depending upon the entities bound, their ratio, and the number or quantity of entities eg. cells requiring isolation, and can readily

be determined according to need. For example, in the case of positive cell selection mentioned above, the ratio of magnetic particles to target cells may vary in different systems and with different applications, and  
5 different amounts of the secondary antibody will accordingly be required to detach the cell from the particles.

Conditions for detachment may also be varied as  
10 appropriate. Thus rosetted cells, suspended in a suitable medium, may simply be incubated with the secondary antibody at ambient temperature. Alternatively the temperature may be reduced eg. to 4°C or raised eg. to 37°C. Best results are obtained by  
15 incubating on an apparatus providing both gentle tilting and rotation.

When the method of the invention is to be used in the isolation of cells, the secondary antibody is normally  
20 obtained from a different species to that of the cells to be isolated. Mice, rats, sheep, swine and rabbits are all particularly suitable as sources of antibody. Thus for example in the isolation of human cells, the anti-antigen may conveniently be raised in mice, and the  
25 anti-immunoglobulin (Ig) antibody is an anti-mouse Ig (eg. as an anti-mouse-Fab) antibody raised in a different species such as sheep, goat or rabbits. Moreover if the cells to be isolated are human, it is advisable to remove all human Ig cross reactivity by  
30 passing the antibody/serum down a human-Ig column. In the case of a polyclonal secondary antibody preparation this may be obtained as the globulin fraction of serum following the ammonium sulphate precipitation.

35 The various reactants in the method of the invention are conveniently supplied in kit form. Thus in a third aspect, the present invention provides a kit comprising:

(i) a particulate solid support, preferably magnetic particles, carrying an anti-hapten or anti-antigen against a target antigen or hapten;

5 (ii) an antibody, or fragment thereof, binding with said anti-hapten or anti-antigen.

In a fourth aspect the invention provides a reagent comprising, for use in the method of the invention, an  
10 antibody or fragment thereof, binding with an anti-antigen or anti-hapten directed against a target antigen or hapten. The reagent according to the invention is conveniently supplied in lyophilised form, or as a sterile filtered buffered solution eg in 0.15M phosphate  
15 buffered saline (PBS) at pH 7.4.

The invention will now be further described by way of the following non-limiting Example(s).

EXAMPLE 1DETACHMENT OF BEADS FROM CELLS

5 5.10<sup>6</sup> Daudi cells (Kvalheim G. et al, Bone Marrow Transplantation 1988; 3, 31-41) were incubated with  
5.10<sup>7</sup> Dynabeads M-450 Pan B (CD 19, Clone AB1, available  
from Dynal AS, Oslo, Norway) on a Rock-N-Roller  
(Lasenco, Lenco, Breda, the Netherlands) platform at 4°C  
10 for 15 minutes to form rosettes. To detach the beads  
from the rosetted cells (in 0.5ml RPMI (1% FBS)) 100μl  
affinity purified goat anti-mouse-Fab (1.4mg/ml) was  
added to the rosettes. The mixture was kept at 4°C  
until the beads detached. For the described  
15 antigen/antibody system complete detachment occurred  
within 10-15 minutes leaving the cell with an intact  
antigen with no antibody bound. Similar results are  
obtained using sheep anti-mouse Fab or anti-mouse Fc.

20 EXAMPLES 2 TO 12

Following the protocol described in Example 1,  
successful detachment was observed in the following  
antigen/antibody systems. In Examples 2, 5, 6 and 7,  
25 antibody coated Dynabeads M-450 - CD4, CD8 or CD19 were  
obtained from Dynal AS. In the remaining Examples, the  
mouse monoclonal antibodies were coupled directly on to  
uncoated Dynabeads obtained from Dynal AS except  
Examples 10 and 11 where the antibodies were coupled to  
30 Dynabeads M-450 coated with sheep anti-mouse Ig.  
The antibodies used in the Examples are available from  
the following sources:

Examples 2 and 6	: Dynal AS, Oslo, Norway
Examples 3, 5 and 12	: Fred Hutchinson, Cancer
35	Research Centre, Seattle, USA
Examples 4, 10 and 12	: Biosys, France
Example 8	: Institute of Molecular

11

Genetics, Praha

Example 9

: Serological Reagents Ltd.,  
East Grinstead, UK

Example 11

: The Norwegian Radium Hospital,  
Oslo

5

	<u>EXAMPLE</u>	<u>ANTIGEN/ANTIBODY</u>	<u>CELL</u>
	2	CD19/AB1	Daudi cells
10	3	CD34/12,8	KG 1a cells
	4	CD34/B1-3C5	KG 1a cells
	5	CD4/66.1	T Helper/inducer cells
	6	CD8/5C2	T suppressor/ cytotoxic cell
15	7	CD19/AB1	pan B cells
	8	CD3/MEM.92	pan T cells
	9	CD10/RFAL3	Lymphoid progenitor cells
	10	CD13/MAS 392 P	Monocyte, granulocyte
20	11	CD24/ML5/ML1/32D12	B cells, granulocyte
	12	CD34/12.8,/B1-3C5	Haemopoietic precursor cell

Example 13

T and B cells are detached using the following protocol:

- 5     1.     Cells are positively isolated using antibody coated  
         Dynabeads eg. Dynabeads M-450 CD4, CD8 or CD19, as  
         recommended by the manufacturer (Dynal AS).
2.     The rosetted cells are resuspended in tissue  
10        culture medium (eg. 100  $\mu$ l of RPMI 1640/FCS).
3.     Goat or sheep anti-mouse Ig is added to the  
         rosetted cells.
- 15     4.     The cells are incubated for 45-60 minutes at  
         ambient temperature on an apparatus providing both  
         gentle tilting and rotation. Care is taken that  
         the cells remain in the bottom of the test tube  
         during agitation.
- 20     5.     The released beads are removed by placing the test  
         tube in a magnetic particle concentrator (MPC from  
         Dynal AS) for 2-3 minutes.
- 25     6.     The cell suspension is pipetted from the test tube  
         while the beads are attached to the wall of the  
         tube by the MPC.
7.     To obtain the residual cells, the detached beads  
30        are washed 2-3 times in culture medium (RPMI  
         1640/FCS or similar) and the supernatant is  
         collected.
8.     The detached cells are washed 2-3 times to remove  
35        the secondary antibody from the solution.
9.     The cells are resuspended in an appropriate buffer.

The efficiency of detachment increases with the amount of secondary antibody applied.

Results obtained using the above protocol show that  
5 cells remain viable following detachment and antigen expression is unperturbed. Typical results are as follows:

Characterization of the detached cells

10

Purity: >99%  
Viability: >98%

Antigen expression of the detached cells

15

B cells: Unperturbed expression of CD5, CD19, CD20, CD21, CD23, CD24, CD37, CD40, CD45, CD75 and CD78. Expression of the CD69 activation antigen was not induced during the isolation/  
20 detachment procedure. The isolated cells could be transformed with Epstein Barr Virus (EBV).

T cells: Unperturbed expression of CD3, CD4 and CD8. More than 98% of the isolated cells express  
25 CD2. Expression of activation antigens such as CD25 (Tac), CD23, CD69 and 4F2 was not induced during the isolation/detachment procedure.

30 Activation status of the freshly isolated cells

>90% of the cells were in the Go (resting) phase as measured by cellular volume distribution, lack of expression of  
35 activation antigens and chromatin structure.

14

The isolated cells were stimulated in vitro using anti- $\mu$  heavy chain + B cell growth factor (low molecular weight BCGF) for B cells or anti-CD3 + IL-2 for T cells. The following early and late activation parameters were demonstrated after stimulation:

5

Early activation parameters:

10

Expression of activation antigens (CD69 on B cells, CD25 on T cells).

Volume increase.

Bulk RNA synthesis ( $^3\text{H}$ -uridine incorporation).

Late activation parameters:

15

DNA synthesis ( $^3\text{H}$ -thymidine incorporation). Cell division (flow cytofluorometric cell cycle analysis).

Example 14Antigen Preparation5 (a) Mouse immunoglobulin:

Serum from healthy, unimmunized Balb C mice was added to 1M NaCl, the pH was adjusted with 0.1 M NaOH to 8.5, the preparation was cooled to 4°C and passed through a  
10 Sepharose-Protein A (Pharmacia) column adjusted to PBS/1 M NaCl, pH 8.5 at 4°C. After eluting the serum (10 ml) through the column (bed volume 15 ml) and washing with PBS/1 M NaCl, pH 8.5 at 4°C, the bound mouse IgG was  
15 eluted with 0.2 M acetate pH 4.0. This IgG was immediately neutralized with solid Tris concentrated with collodium bags (Schleicher & Schuell UH 100/25 Ultrahulsen) and dialysed against PBS pH 7.3.

20 (b) Mouse monoclonal IgG1 Fab and Fc fragments:

Ascites from Balb C mice growing hybridoma cell line 32D12 (IgG1) was added to 1 M NaCl concentration, the pH was adjusted with 0.1 M NaOH to 8.5, the preparation was cooled to 4°C and passed through a Sepharose-Protein A  
25 (Pharmacia) column adjusted to PBS/1 M NaCl, pH 8.5 at 4°C. After eluting the ascites (5 ml) through the column (bed volume 15 ml) and washing with PBS/1 M NaCl, pH 8.5 at 4°C, the bound mouse IgG1 was eluted with 0.2 M acetate pH 4.0. This IgG was immediately neutralized  
30 with solid Tris concentrated with collodium bags (Schleicher & Schuell UH 100/25 Ultrahulsen) and dialysed against PBS pH 7.3. A sample of the isolated IgG1 was digested (1:100 wt/wt) with papain (Sigma No P-3125) in the presence of 0.01 M DTT (Sigma No D-0632)  
35 and digested for 1 hour at 37°C. The digestion was stopped by adding iodoacetamide (Sigma No. I-6125) to

0.25 M concentration. After dialysis against PBS, the sample was added to 1 M NaCl concentration, the pH was adjusted to 8.5 and the temperature to 4°C and passed through a Sepharose-Protein A (Pharmacia) column  
5 adjusted to PBS/1 M NaCl, pH 8.5 at 4°C. After eluting the sample through the column (bed volume 15 ml) the column was washed with PBS/1 M NaCl, pH 8.5 at 4°C to elute the Fab fragments, and the bound mouse IgG1 Fc fragments were then eluted with 0.2 M acetate pH 4.0.  
10 These IgG1 Fab and Fc fragments were immediately neutralized with solid Tris concentrated with collodium bags (Schleicher & Schuell UH 100/25 Ultrahulsen) and dialysed against PBS pH 7.3.

15 Preparation of Secondary Antibody

1. 50-250 µg antigen prepared according to (a) or (b) above in 0.5 ml phosphate buffered saline (PBS), pH 7.3 mixed with 0.75 ml Freund's Complete Adjuvant  
20 is administered to the sheep subcutaneously in several places on the back of the animal (50%) and intramuscularly in the thigh (50%).
2. After 2 weeks rest, this treatment is repeated.
- 25 3. After 2 weeks, this treatment is repeated once more.
4. After 2 weeks rest the animal is bled (about 500 ml  
30 whole untreated blood).
5. Bleeding is repeated each 2 weeks and if necessary a booster dose of antigen is given once a month.
- 35 6. The sheep is kept in production for about a year before it is terminated (or prolonged for about 6 months).

CLAIMS

1. A method of cleaving an antigen/anti-antigen or  
hapten/anti-hapten linkage joining two particles  
5 comprising reacting said linkage with a secondary  
antibody, or fragment thereof, binding to said  
anti-antigen or anti-hapten.
2. A method as claimed in claim 1 wherein the  
10 secondary antibody or fragment thereof binds to the  
Fab region of said anti-antigen or anti-hapten.
3. A method as claimed in claim 1 or claim 2 wherein  
the secondary antibody and/or anti-hapten or anti-  
15 antigen is a complete antibody.
4. A method as claimed in claim 1 or claim 2 wherein  
the anti-hapten or anti-antigen is an antibody  
fragment retaining binding activity.  
20
5. A method as claimed in any one of claims 1 to 4  
wherein the secondary antibody is an IgG or IgM  
antibody, or fragment thereof.
- 25 6. A method as claimed in any of claims 1 to 5 wherein  
the secondary antibody is polyclonal.
7. A method as claimed in any one of claims 1 to 6  
wherein in said linkage, the anti-antigen or anti-  
30 hapten is attached to a particulate solid support.
8. A method as claimed in any one of claims 1 to 7  
wherein the linkage joins an anti-antigen or anti-  
hapten carrying particulate solid support and  
35 surface-antigen or hapten carrying cells.

9. A method as claimed in any one of claims 1 to 6 wherein the secondary antibody is attached to particles.

5 10. A method of positively isolating a target cell-type from a mixed population of cells wherein an anti-antigen is bound to an antigen on said target cell, said anti-antigen being attached to magnetic particles, before or after binding to said target  
10 cells, whereby to link said particles to said cells, the magnetic particles and attached cells are isolated from the mixed population of cells by magnetic aggregation and the target cell is released from said magnetic particle by the  
15 addition of a secondary antibody, or fragment thereof, binding to said anti-antigen.

11. A method as claimed in claim 10 wherein the  
20 secondary antibody is raised in a different species from that of the target cell.

12. A kit comprising:

25 (i) a particulate solid support carrying an anti-antigen or anti-hapten against a target antigen or hapten;

(ii) an antibody, a fragment thereof, binding with  
30 said anti-antigen or anti-hapten.

14. A kit as claimed in claim 12 wherein the solid support comprises magnetic particles.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 91/00671

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC<sup>5</sup>: G 01 N 33/53, 33/546, 33/569

## II. FIELDS SEARCHED

Minimum Documentation Searched <sup>7</sup>

Classification System <sup>1</sup>

Classification Symbols

IPC<sup>5</sup>

G 01 N

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>

## III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup>

Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	EP, A, 0323829 (E.I. DU PONT DE NEMOURS & CO.) 12 July 1989 see columns 1-5, 12 --	1-14
Y	US, A, 4861705 (S. MARGEL) 29 August 1989 see the abstract; column 2, lines 23-35; column 10, lines 40-68 --	1-14
Y	EP, A, 0170302 (L'ASSOCIATION INTERNATIONALE A BUT SCIENTIFIQUE, DITE: INSTITUTE INTERNATIONAL DE PATHOLOGIE CELLULAIRE ET MOLECULAIRE) 5 February 1986 see the whole document --	1-14
A	WO, A, 8802776 (P. GRANDICS et al.) 21 April 1988 see page 2, line 37 - page 3, line 12; page 6, line 1 - page 7, line 18 -- ./.	1, 10

\* Special categories of cited documents: <sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

11th July 1991

Date of Mailing of this International Search Report

29. 08. 91

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

miss T. MORTENSEN

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	EP, A, 0119629 (NEW ENGLAND NUCLEAR CORP.) 26 September 1984  -----	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9100671

SA 46229

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 20/08/91  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0323829	12-07-89	AU-A- 2613988 EP-A- 0398880 WO-A- 8906280	01-08-89 28-11-90 13-07-89
US-A- 4861705	29-08-89	None	
EP-A- 0170302	05-02-86	BE-A- 900023 JP-A- 61017957	15-10-84 25-01-86
WO-A- 8802776	21-04-88	AU-A- 8173387	06-05-88
EP-A- 0119629	26-09-84	US-A- 4536479 CA-A- 1225590 JP-A- 59180362	20-08-85 18-08-87 13-10-84

